Published in Clin Pharmacol Ther on June 06, 2012
Physiologically based pharmacokinetic modeling at the extremes of age. Clin Pharmacol Ther (2012) 1.07
Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant (2013) 1.06
Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol (2013) 1.01
A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J (2013) 0.86
Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol (2015) 0.85
Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol (2015) 0.85
Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J (2014) 0.85
Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit (2015) 0.82
Optimizing drug development of anti-cancer drugs in children using modelling and simulation. Br J Clin Pharmacol (2013) 0.81
A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br J Pharmacol (2014) 0.80
Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. Clin Pharmacokinet (2014) 0.80
A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. AAPS J (2013) 0.80
Influence of Food on Paediatric Gastrointestinal Drug Absorption Following Oral Administration: A Review. Children (Basel) (2015) 0.78
Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. J Pharm Biomed Anal (2013) 0.78
Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn (2016) 0.78
Clinical pharmacology in neonates: small size, huge variability. Neonatology (2014) 0.77
Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert Rev Clin Pharmacol (2013) 0.77
Pharmacokinetic studies in infants using minimal-risk study designs. Curr Clin Pharmacol (2014) 0.77
Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. Clin Pharmacokinet (2015) 0.76
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. Br J Clin Pharmacol (2015) 0.75
Response to "Physiologically based pharmacokinetic modeling at the extremes of age". Clin Pharmacol Ther (2012) 0.75
Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model. Int J Antimicrob Agents (2015) 0.75
First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. Clin Pharmacokinet (2014) 0.75
Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval. Clin Ther (2016) 0.75
Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. Drug Metab Dispos (2016) 0.75
Translational learning from clinical studies predicts drug pharmacokinetics across patient populations. NPJ Syst Biol Appl (2017) 0.75
Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data. Clin Pharmacokinet (2017) 0.75
Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res (1999) 1.35
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol (1998) 1.24
Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol (1998) 1.17
Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther (2004) 1.11
Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol (1996) 0.98
Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther (1999) 0.97
The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res (2006) 0.93
Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence. J Chromatogr B Biomed Sci Appl (2001) 0.87
Pharmacokinetic profile of spectinomycin in rats. Pharmazie (2013) 0.84
Long-term beta adrenoceptor-mediated alteration in contractility and expression of phospholamban and sarcoplasmic reticulum Ca(++)-ATPase in mammalian ventricle. J Pharmacol Exp Ther (1998) 0.83
A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm Res (2006) 0.83
Evaluation of regional limb perfusion with amikacin using the saphenous, cephalic, and palmar digital veins in standing horses. J Vet Pharmacol Ther (2012) 0.82
Determination of carvedilol in human cardiac tissue by high-performance liquid chromatography. J Chromatogr Sci (2001) 0.82
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol (1997) 0.81
Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res (2000) 0.80
Transrepression and transactivation potencies of inhaled glucocorticoids. Pharmazie (2008) 0.79
Primary HHV 6 infection after liver transplantation with acute graft rejection and multi-organ failure: successful treatment with a 2.5-fold dose of cidofovir and reduction of immunosuppression. Pediatr Transplant (2010) 0.78
Utility of N-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery. Pediatr Cardiol (2006) 0.78
Biochemical mechanism(s) of stunning in conscious dogs. Am J Physiol Heart Circ Physiol (2000) 0.77
Digitoxin intoxication during concomitant use of amiodarone. Eur J Clin Pharmacol (1998) 0.77
Inositol-1,4,5-trisphosphate increase by diadenosine tetraphosphate in preparations from failing human myocardium. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.76
Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. Ann Oncol (2013) 0.75
Response to "Physiologically based pharmacokinetic modeling at the extremes of age". Clin Pharmacol Ther (2012) 0.75
Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. Pharmazie (2000) 0.75
Clinical PK/PD modelling as a tool in drug development of corticosteroids. Int J Clin Pharmacol Ther (1997) 0.75
Lymphocyte abnormalities in patients with macro- and micro-prolactinoma: different effects of bromocriptine treatment in the two groups. Int J Neurosci (1990) 0.75
Termination of automatic atrial tachycardia in an infant by adequate sotalol dosing. Indication of clinically relevant age-dependent pharmacokinetics of sotalol. Eur J Clin Pharmacol (2001) 0.75
Association between increased 5-HIAA plasma concentrations and postoperative nausea and vomiting in patients undergoing general anaesthesia for surgery. Eur J Anaesthesiol (2001) 0.75
The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. Resuscitation (1995) 0.75
[Morphological and functional features of cytostatic drug resistance and the effects of MDR modulators]. Pharmazie (1996) 0.75
Combination treatment in autoimmune diseases: systemic lupus erythematosus. Springer Semin Immunopathol (2001) 0.75